MALARIA

This study tests whether giving infants an investigational antibody (L9LS) before a malaria vaccine (R21/Matrix-M) is safe and helps the vaccine work better. About 180 healthy infants in Mali, aged 1 to 12 months, will receive either the antibody or a placebo, followed by the vac…

This early-stage study tests a new malaria vaccine made from genetically weakened parasites. The goal is to see if it is safe and can train the immune system to fight malaria without causing the disease. About 22 healthy adults who have never had malaria will receive the vaccine …

This large Phase 3 trial is testing whether the R21/Matrix-M vaccine can protect young children (5-36 months old) from getting malaria. About 4,800 children in Africa are taking part. The study compares the vaccine to a placebo and will check how well it works over 12 months, as …

This study tests whether an experimental malaria vaccine (PfSPZ) is safe for pregnant women. About 400 healthy pregnant women in Mali will receive either the vaccine or a placebo. Researchers will monitor the mothers and their babies for side effects and birth outcomes for up to …

This study tests two new types of mosquito nets to see if they prevent malaria better than standard nets. About 1,650 children and adults in central Côte d'Ivoire will use these nets, and researchers will track malaria cases and infections over up to three years. The goal is to f…

This study tests whether giving young children monthly malaria prevention medicine (dihydroartemisinin-piperaquine) from 8 weeks old up to 1 or 2 years of age can help their bodies build stronger immunity against malaria. About 924 children in Uganda will be followed until age 4 …

This study is tracking how often people of all ages get malaria in two villages in Liberia. Researchers will also collect mosquitoes from homes each month. The goal is to gather information that could help make a future malaria vaccine more effective in Liberia. About 396 healthy…

This study was designed to see if giving a monoclonal antibody (L9LS) before the R21/Matrix-M malaria vaccine changes how well the vaccine works. It planned to enroll healthy adults and infants in Mali. However, the study was withdrawn before any participants were enrolled, so no…